Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

Overview

cited authors

Pratley, Richard E.; Aroda, Vanita R.; Catarig, Andrei-Mircea; Lingvay, Ildiko; Luedemann, Joerg; Yildirim, Emre; Viljoen, Adie

authors

Pratley, Richard Edwin, MD

Publication Date

January 1, 2020

webpage

Web of Science

published in

BMJ OPEN Journal

Research

keywords

clinical trials
diabetes &
endocrinology
general diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.